# Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

> **NCT05935527** · PHASE1 · COMPLETED · sponsor: **Peregrine Ophthalmic** · enrollment: 50 (actual)

## Conditions studied

- Lower Eyelid Steatoblepharon

## Interventions

- **DRUG:** POLAT-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05935527
- **Lead sponsor:** Peregrine Ophthalmic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-28
- **Primary completion:** 2024-09-19
- **Final completion:** 2024-11-18
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935527, "Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05935527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*